Poly(ethylene glycol) modification enhances penetration of fibroblast growth factor 2 to injured spinal cord tissue from an intrathecal delivery system

Journal of Controlled Release : Official Journal of the Controlled Release Society
Catherine E KangMolly S Shoichet

Abstract

There is no effective treatment for spinal cord injury and clinical drug delivery techniques are limited by the blood-spinal cord barrier. Our lab has developed an injectable drug delivery system consisting of a biopolymer blend of hyaluronan and methylcellulose (HAMC) that can sustain drug release for up to 24h in the intrathecal space. Fibroblast growth factor 2 (FGF2) has great potential for treatment of spinal cord injury due to its angiogenic and trophic effects, but previous studies showed no penetration into spinal cord tissue when delivered locally. Conjugation to poly(ethylene glycol) (PEG) is known to improve penetration of proteins into tissue by reducing clearance and providing immunogenic shielding. We investigated conjugation of PEG to FGF2 and compared its distribution relative to unmodified FGF2 in injured spinal cord tissue when delivered intrathecally from HAMC. Importantly, PEG conjugation nearly doubled the concentration of FGF2 in the injured spinal cord when delivered locally and, contrary to previous reports, we show that some FGF2 penetrated into the injured spinal cord using a more sensitive detection technique. Our results suggest that PEGylation of FGF2 enhanced tissue penetration by reducing its rate...Continue Reading

Citations

Feb 21, 2013·Nature Chemistry·Thi H NguyenHeather D Maynard
Feb 26, 2011·Journal of Tissue Engineering·Ye-Rang YunHae-Won Kim
Feb 19, 2016·Proceedings of the National Academy of Sciences of the United States of America·Drew L SellersSuzie H Pun
Jul 27, 2010·Biomaterials·M Douglas BaumannMolly S Shoichet
Dec 29, 2011·Journal of the American Chemical Society·Katarina Vulic, Molly S Shoichet
Apr 16, 2014·Journal of Biomedical Materials Research. Part a·Mirhamed HajimiriRassoul Dinarvand
Aug 1, 2015·Journal of Controlled Release : Official Journal of the Controlled Release Society·Anup TuladharMolly S Shoichet
May 3, 2016·Materials Science & Engineering. R, Reports : a Review Journal·Michael C KoettingNicholas A Peppas
Dec 2, 2010·Journal of Controlled Release : Official Journal of the Controlled Release Society·Hunghao ChuYadong Wang
Apr 20, 2013·Biomaterials·Fabio Zomer VolpatoPaul D Dalton
Apr 26, 2016·Journal of Biotechnology·Xianlong YeDeshan Li
Aug 23, 2011·Biomacromolecules·Ryan G Wylie, Molly S Shoichet
Nov 14, 2016·International Journal of Pharmaceutics·Farideh OrdikhaniSilviya Petrova Zustiak
Apr 1, 2014·Brain and Behavior·Nimer Adeeb, Martin M Mortazavi
Nov 29, 2015·Proceedings of the Institution of Mechanical Engineers. Part H, Journal of Engineering in Medicine·Teresa RussoLuigi Ambrosio
Jan 24, 2018·Biomedical Materials·Agnes E HaggertyMartin Oudega
Aug 12, 2014·Nature Reviews. Drug Discovery·Samir MitragotriRobert Langer
Mar 30, 2012·Biomedical Materials·Malgosia M PakulskaMolly S Shoichet
Apr 18, 2020·Growth Factors·María Del Carmen Díaz-GalindoJ Luis Quintanar
Jun 10, 2020·Journal of Cellular and Molecular Medicine·Xiaoli HuJian Xiao
Aug 2, 2017·Neural Regeneration Research·Xian-Bin KongZhong-Lei Sun
Oct 25, 2020·Pharmaceutics·Nkiruka IbeanuSahar Awwad
Nov 25, 2019·Biomedical Physics & Engineering Express·Patrícia I MorgadoJuan Larrain

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.